aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Peak Bio, a biopharmaceutical company, was founded with the mission to develop innovative therapies targeting significant unmet medical needs in oncology and inflammatory diseases. The company focuses on creating treatments for complex conditions, including rare and specialty diseases and cancer. With a robust portfolio of small molecules, antibodies, and antibody-drug conjugates (ADCs), Peak Bio aims to deliver best-in-class therapeutics to improve patient outcomes.
The experienced management team at Peak Bio brings extensive industry expertise, having previously led successful drug development initiatives. The company has garnered attention from notable investors and has achieved key milestones in advancing its therapeutic candidates through various stages of clinical development. Peak Bio's impact is marked by its commitment to addressing critical healthcare challenges and improving the lives of patients with severe and underserved medical conditions.
Operating Status
Active
Main Product(s)
Drug Development
Technology
Biotech
Model Types
Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
Global
When was Peak Bio founded?
Peak Bio was founded in 2015.
Where is Peak Bio's headquarters located?
Peak Bio's headquarters is located in Palo Alto, CA, US.
How many employees does Peak Bio have?
Peak Bio has 30 employees as of Feb 5, 2024.
How much has Peak Bio raised to-date?
As of July 05, 2023, Peak Bio has raised a total of $25M (USD) since Nov 2, 2022.
Add Comparison
Total Raised to Date
$25M
USD
Last Update Nov 2, 2022
Total Employees Over Time
30
As of Feb 2024
Peak Bio Address
3350 W Bayshore Rd
suite 100
Palo Alto,
California
94303
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts